HSBC Holdings
ARQT icon

HSBC Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

HSBC Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,057
Closed -$139K – 2709
2025
Q2 		$139K Sell
10,057
-7,701
-43% -$108K ﹤0.01% 2784
2025
Q1 		$271K Buy
17,758
+207
+1% +$2.92K ﹤0.01% 2437
2024
Q4 		$248K Buy
17,551
+4,719
+37% +$51.7K ﹤0.01% 2601
2024
Q3 		$120K Sell
12,832
-1,267
-9% -$12.5K ﹤0.01% 2764
2024
Q2 		$131K Sell
14,099
-492,187
-97% -$4.45M ﹤0.01% 2678
2024
Q1 		$5.01M Buy
506,286
+362,351
+252% +$2.7M ﹤0.01% 1098
2023
Q4 		$465K Hold
143,935
– – ﹤0.01% 2078
2023
Q3 		$764K Sell
143,935
-880
-0.6% -$7.48K ﹤0.01% 1811
2023
Q2 		$1.38M Buy
144,815
+23,280
+19% +$258K ﹤0.01% 1581
2023
Q1 		$1.34M Sell
121,535
-4,286
-3% -$62K ﹤0.01% 1661
2022
Q4 		$1.86M Sell
125,821
-4,903
-4% -$85.7K ﹤0.01% 1709
2022
Q3 		$2.5M Buy
130,724
+18,967
+17% +$430K ﹤0.01% 1463
2022
Q2 		$2.38M Buy
111,757
+19,769
+21% +$406K ﹤0.01% 1504
2022
Q1 		$1.77M Buy
91,988
+57,465
+166% +$972K ﹤0.01% 1664
2021
Q4 		$810K Buy
+34,523
New +$687K ﹤0.01% 2165
2021
Q1 		– Sell
-9,010
Closed -$255K – 2719
2020
Q4 		$255K Buy
+9,010
New +$221K ﹤0.01% 2677

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HSBC Holdings's ARQT Position: Q3 2025 in Review

HSBC Holdings sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 10,057 shares — an estimated $139K sold.

HSBC Holdings first reported a position in ARQT in Q4 2020 and held it in 16 quarters. The position peaked at $5.01M in Q1 2024. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • HSBC Holdings reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 10,057 Arcutis Biotherapeutics shares in Q3 2025, an estimated $139K.
  • HSBC Holdings first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 16 quarters.
  • HSBC Holdings's Arcutis Biotherapeutics position peaked at $5.01M in Q1 2024.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.